drugset / Trial / NCT01233947
Study of AFP464 +/- Faslodex in ER + Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AFP464 | Small molecule | 74 mg/m2 | Intravenous |
| Subject | Fulvestrant | Small molecule | — | — |